JP2024516680A - 敗血症の早期検出用のｉｌ６マーカーパネル - Google Patents

敗血症の早期検出用のｉｌ６マーカーパネル Download PDF

Info

Publication number
JP2024516680A
JP2024516680A JP2023566809A JP2023566809A JP2024516680A JP 2024516680 A JP2024516680 A JP 2024516680A JP 2023566809 A JP2023566809 A JP 2023566809A JP 2023566809 A JP2023566809 A JP 2023566809A JP 2024516680 A JP2024516680 A JP 2024516680A
Authority
JP
Japan
Prior art keywords
biomarker
subject
amount
assessing
cardiac troponin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516680A5 (https=
Inventor
グリューネバルト，フェリックス
イェーガー，ヴィクトル・ヨハン・ラウル
クラマー，マルティン
シュッツ，フィリップ
ホルタイ，マリア フォン
ヴェーバー，シュテフェン
ベクマイヤー，ハイケ
ビーンヒューズ－テレン，ウルスラ－ヘンリケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2024516680A publication Critical patent/JP2024516680A/ja
Publication of JP2024516680A5 publication Critical patent/JP2024516680A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023566809A 2021-04-30 2022-04-29 敗血症の早期検出用のｉｌ６マーカーパネル Pending JP2024516680A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21171496.9 2021-04-30
EP21171496 2021-04-30
PCT/EP2022/061580 WO2022229438A2 (en) 2021-04-30 2022-04-29 Il6 marker panels for early detection of sepsis

Publications (2)

Publication Number Publication Date
JP2024516680A true JP2024516680A (ja) 2024-04-16
JP2024516680A5 JP2024516680A5 (https=) 2025-04-24

Family

ID=75746438

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566809A Pending JP2024516680A (ja) 2021-04-30 2022-04-29 敗血症の早期検出用のｉｌ６マーカーパネル

Country Status (5)

Country Link
US (1) US20240219405A1 (https=)
EP (1) EP4330686A2 (https=)
JP (1) JP2024516680A (https=)
CN (1) CN117242350A (https=)
WO (1) WO2022229438A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025064996A1 (en) * 2023-09-22 2025-03-27 The General Hospital Corporation Systems and methods for early prediction of sepsis based on biomarkers of bacterial metabolism

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510478A (ja) * 2005-10-03 2009-03-12 バイオサイト インコーポレイテッド 全身性炎症反応症候群の診断および／または予後診断のための方法および組成物
JP2010529468A (ja) * 2007-06-12 2010-08-26 ハンサ メディカル アクチボラゲット 診断方法
JP2010538282A (ja) * 2007-09-07 2010-12-09 ウニヴェルズィテート・ツューリヒ ヒト敗血症を測定する方法
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
JP2013512434A (ja) * 2009-11-25 2013-04-11 ホロジック，インコーポレイテッド 羊膜内感染の検出
JP2013521480A (ja) * 2010-03-02 2013-06-10 エフ．ホフマン−ラ ロシュ アーゲー 無症候性患者における全身性炎症反応症候群およびセプシスの早期診断および予測に基づくｉｌ−６の検出
US20150362509A1 (en) * 2013-01-28 2015-12-17 Vanderbilt University Method for Differentiating Sepsis and Systemic Inflammatory Response Syndrome (SIRS)
WO2020169819A1 (en) * 2019-02-21 2020-08-27 B.R.A.H.M.S Gmbh Diagnosis or prognosis of postsurgical adverse events

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190872B1 (en) * 1994-05-06 2001-02-20 Gus J. Slotman Method for identifying and monitoring patients at risk for systemic inflammatory conditions and apparatus for use in this method
CA2476597C (en) 2002-02-28 2011-05-17 Metanomics Gmbh & Co. Kgaa Mass spectrometry method for analysing mixtures of substances
US20090197794A1 (en) 2005-07-13 2009-08-06 Aird William C Methods of Diagnosing and Treating an Inflammatory Response
CN103123359B (zh) 2007-08-03 2015-07-29 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用
RU2015123307A (ru) * 2008-03-26 2015-11-27 Теранос, Инк. Способ и система для прогнозирования клинических исходов
RU2016112915A (ru) 2013-09-05 2017-10-09 Эф-Ай-Оу Корпорейшн Биомаркеры для раннего выявления критической или угрожающей жизни ответной реакции на заболевание и/или ответной реакции на лечение

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009510478A (ja) * 2005-10-03 2009-03-12 バイオサイト インコーポレイテッド 全身性炎症反応症候群の診断および／または予後診断のための方法および組成物
JP2010529468A (ja) * 2007-06-12 2010-08-26 ハンサ メディカル アクチボラゲット 診断方法
JP2010538282A (ja) * 2007-09-07 2010-12-09 ウニヴェルズィテート・ツューリヒ ヒト敗血症を測定する方法
JP2013512434A (ja) * 2009-11-25 2013-04-11 ホロジック，インコーポレイテッド 羊膜内感染の検出
JP2013521480A (ja) * 2010-03-02 2013-06-10 エフ．ホフマン−ラ ロシュ アーゲー 無症候性患者における全身性炎症反応症候群およびセプシスの早期診断および予測に基づくｉｌ−６の検出
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
US20150362509A1 (en) * 2013-01-28 2015-12-17 Vanderbilt University Method for Differentiating Sepsis and Systemic Inflammatory Response Syndrome (SIRS)
WO2020169819A1 (en) * 2019-02-21 2020-08-27 B.R.A.H.M.S Gmbh Diagnosis or prognosis of postsurgical adverse events

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HAILEI GUO ET AL.: "MicroRNA-495 serves as a diagnostic biomarker in patients with sepsis and regulates sepsis-induced i", EUROPEAN JOURNAL OF MEDICAL RESEARCH, vol. 24(1), JPN7026001136, 2019, pages 37, ISSN: 0005819976 *
JAYSHIL J. PATEL ET AL.: "The Association of Serum Bilirubin Levels on the Outcomes of Severe Sepsis", JOURNAL OF INTENSIVE CARE MEDICINE, vol. 30(1), JPN7026001137, 2015, pages 23 - 29, ISSN: 0005819977 *
M. MARTIN-FERNANDEZ ET AL.: "Endothelial dysfunction is an early indicator of sepsis and neutrophil degranulation of septic shock", BJS OPEN, vol. 4(3), JPN7026001138, 2020, pages 524 - 534, ISSN: 0005819978 *
MARIA BERGQUIST ET AL.: "TNFR1, TNFR2, neutrophil gelatinase-associated lipocalin and heparin binding protein in identifying", SCIENTIFIC REPORTS, vol. 10(1), JPN6026010851, 2020, pages 1 - 11, ISSN: 0005819979 *
MARTIN SEBASTIAN WINKLER ET AL.: "Decreased serum concentrations of sphingosine-1-phosphate in sepsis", CRITICAL CARE, vol. 19, JPN7026001135, 2015, pages 372, ISSN: 0005819975 *
RONI LEHMANN-WERMAN ET AL.: "Monitoring liver damage using hepatocyte-specific methylation markers in cell-free circulating DNA", JCI INSIGHT, vol. 3(12), JPN7026001139, 2018, pages 120687, ISSN: 0005819980 *

Also Published As

Publication number Publication date
WO2022229438A3 (en) 2022-12-15
US20240219405A1 (en) 2024-07-04
EP4330686A2 (en) 2024-03-06
CN117242350A (zh) 2023-12-15
WO2022229438A2 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
JP2026048754A (ja) 敗血症の早期検出用のｐｃｔマーカーパネル
JP2024516680A (ja) 敗血症の早期検出用のｉｌ６マーカーパネル
JP2024516677A (ja) 敗血症の早期検出用のｎｇａｌマーカーパネル
JP2024516678A (ja) 敗血症の早期検出用のｓｔｒｅｍ１マーカーパネル
JP2024516001A (ja) 敗血症の早期検出のためのｅｓｍ１マーカーパネル
JP2024516679A (ja) 敗血症の早期検出用のｉｇｆｂｐ７マーカーパネル
JP2024515086A (ja) 敗血症の早期検出のためのｇｄｆ１５マーカーパネル
JP2024516681A (ja) 敗血症の早期検出のためのｓＦｌｔ１マーカーパネル
JP2024537774A (ja) 敗血症の早期検出のためのＭＲ－ｐｒｏＡＤＭマーカーパネル
US20240230672A1 (en) Presepsin marker panels for early detection of sepsis
JP2025506704A (ja) 敗血症を早期検出するためのｄｌｌ１マーカーパネル

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260318